EpimAb Biotherapeutics, Inc. is founded in 2015, operates from its headquarter in Room 205, Building No.5, No. 338 Jia Li Lue Road, Zhangjiang Hi-Tech Park, Shanghai Shanghai, Shanghai 201203, CN. The company operates in the Hospitals & Healthcare, Medical Practices sector.
EpimAb Biotherapeutics, Inc. specializes in Bi-specific antibody development, FIT-Ig technology, Antigen binding, Biochemical and biophysical properties analysis, CMC development, Licensing arrangements, and offers services including Novel bi-specific antibodies, FIT-Ig (Fabs in Tandem) platform, and CMC development.
Total Rounds
US$ 120M
Last Round
US$ 120M
Rounds
1
Investors
CMB International Capital Corporation, MiraeAsset Financial Group, Other investors